For the first time, a new study shows that treatment with a progesterone receptor modulator is effective for the treatment of typical symptoms such as irritability and depression in women suffering from PMDS.
The study, which was conducted at Uppsala University, Karolinska Institute and Umeå University, has been published in the medical journal American Journal of Psychiatry.
Image credit: 422694 | Free image via Pixabay
Premenstrual dysphoric disorder (PMDS) is a condition that causes severe mental premenstrual symptoms with a significant negative impact on daily life and is affecting 3-5 per cent of women of childbearing age. Today, the standard treatment is combined with birth control pills or antidepressant serotonin reuptake inhibitors. These treatments are effective but are not suitable for all women.
The present study has investigated the effect of a selective progesterone receptor modulator (ulipristal acetate, UPA) which binds to the progesterone receptor and inhibits its effect in the brain. This substance, which is currently used to treat myoma, blocks ovulation and maintains estradiol and progesterone levels at constant moderate levels.
Researchers from Uppsala University, Karolinska Institute and Umeå University have conducted a double-blind, randomized, placebo-controlled study of 95 women with PMDS showing that UPA effectively reduces mental symptoms such as irritability and depression in these women. The study, published in the American Journal of Psychiatry, furthermore shows that half of the patients who received UPA were completely asymptomatic, compared with 21 per cent in the placebo group.
The results provide increased knowledge about the underlying mechanisms of the symptoms and can hopefully become a new treatment option for women with PMDS.
“It’s extremely fun that the clinical observations in the meeting with patients can be proved in scientific studies, that can lead to women being able to get better help”. Says Helena Kopp Kallner, senior lecturer and chief physician in gynacology at the Department of Clinical Sciences, KIDS.
The drug is only available in one product that’s not on the market today. Hopefully, it will be available for treatment for PMDS in summer next year, depending on what the European Medicines Commission decides.
Source: Karolinska Institute
Leave a Reply